Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2002
10/03/2002WO2002076211A1 Nicotine-containing oral dosage form
10/03/2002WO2002065834A3 Novel formulations of carvedilol
10/03/2002WO2002062766A3 Melanocortin-4 receptor binding compounds and methods of use thereof
10/03/2002WO2002059179A3 Synthesis of high molecular weight non-peptidic polymer derivatives
10/03/2002WO2002057424A3 Nucleic acid delivery formulations
10/03/2002WO2002055097A3 Conjugates of nucleosides with lactosaminated human albumine
10/03/2002WO2002051436A3 Stable enzymatic wound debrider
10/03/2002WO2002034793A3 Rheology modifying copolymer composition
10/03/2002WO2002022677A3 Variants of allergenic proteins of the group 2 of dermatophagoides
10/03/2002WO2002022657A3 Peptide antagonist of multiple chemokine receptors and uses thereof
10/03/2002WO2002017921A3 Paroxetine compositions and processes for making the same
10/03/2002WO2002002751A3 Alteration of cell membrane
10/03/2002WO2001093836A3 Encapsulation of polynucleotides and drugs into targeted liposomes
10/03/2002WO2001076603A1 Medicinal compositions containing camptothecin derivative and ph regulating agent
10/03/2002WO2001064187A8 Anaesthetic formulations
10/03/2002WO2001017508A9 Cationic liposome delivery of taxanes to angiogenic blood vessels
10/03/2002WO2001000041A3 Method of preparing protein agglomerates
10/03/2002US20020143348 Embolic devices capable of in-situ reinforcement
10/03/2002US20020143058 Blending ingredients including a hygroscopic salt of valproic acid, carbomer, and non-hygroscopic additive to form non-hygroscopic stable oral pharmaceutical formulation
10/03/2002US20020143051 Shelf-life
10/03/2002US20020143050 Premixed amiodarone parenteral solution and method for making the same
10/03/2002US20020143038 Parenteral formulation for epothilone analogs
10/03/2002US20020142998 For prophylaxis and therapy
10/03/2002US20020142994 Bisphosphonate conjugates and methods of making and using the same
10/03/2002US20020142972 Antiparasitic formulation
10/03/2002US20020142960 Exposing cells to an aggregate formulation which comprises VP22, or a polypeptide with transport function of VP22, and oligonucleotides or polynucleotides; exposing cells to a disaggregating agent which can promote disaggregation
10/03/2002US20020142955 Therapy of tumors; prodrugs that display a high specificity of action, a reduced toxicity, and an improved stability in blood
10/03/2002US20020142950 Methods for enhancing the bioavailability of a drug
10/03/2002US20020142945 Immunomodulatory methods using carbohydrate antigens
10/03/2002US20020142447 DNA encoding the human serine protease EOS
10/03/2002US20020142446 DNA encoding the human serine protease EOS
10/03/2002US20020142389 Soluble T cell receptor
10/03/2002US20020142359 Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
10/03/2002US20020142051 Hydrogen peroxide disinfectant with increased activity
10/03/2002US20020142046 Protein particles for therapeutic and diagnostic use
10/03/2002US20020142043 Powder containing fat-soluble drug
10/03/2002US20020142041 Gastrointestinal mucosa-adherent matrixes, pharmaceutical preparations and a coating composition
10/03/2002US20020142040 Antibacterial composition for topical administration containing antibiotic
10/03/2002US20020142036 Active substance-containing multi-layer film of hydrophilic polymers crosslinked in situ
10/03/2002US20020142034 Orally disintegrable tablets
10/03/2002US20020142032 Mixture of microcrystalline cellulose and silica
10/03/2002US20020142029 Use of complexes among cationic liposomes and polydeoxyribonucleotides and medicaments
10/03/2002US20020142015 Reducing skin sensitivity
10/03/2002US20020142000 Genetic engineering
10/03/2002US20020141999 Complexing; immunoassay, immunotherapy
10/03/2002US20020141987 Fish serine proteinases and their pharmaceutical and cosmetic use
10/03/2002US20020141980 Convection-enhanced delivery of AAV vectors
10/03/2002US20020141970 Stabilized with chelate compound; storage stability
10/03/2002US20020141947 Biocompatible particles having therapeutic, prophylactic or diagnostic agent, and of given mass mean diameter and aerodynamic diameter; at least 46% of the mass of particles are deposited after the first bifurcation of the lungs
10/03/2002US20020141946 Formulation of dipalmitoylphosphatidyl choline (DPPC), insulin and sodium citrate
10/03/2002US20020141944 Stable pharmaceutical budersonide preparation for producing propellant-free aerosols
10/03/2002US20020141943 Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
10/03/2002US20020141941 PSCA: prostate stem cell antigen and uses thereof
10/03/2002CA2692295A1 Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer
10/03/2002CA2445640A1 Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
10/03/2002CA2445125A1 Microemulsions as precursors to solid nanoparticles
10/03/2002CA2442318A1 Antibodies against cancer
10/03/2002CA2442280A1 A stable pharmaceutical composition of pravastatin
10/03/2002CA2442261A1 Liposome composition for improved intracellular delivery of a therapeutic agent
10/03/2002CA2441940A1 Dental formulation
10/03/2002CA2441824A1 Use of lipoaminoacids as absorption promoters in a pharmaceutical composition
10/03/2002CA2441484A1 Molecular conjugates for use in treatment of cancer
10/03/2002CA2441227A1 Liposome targeting of matrix metalloproteinase inhibitors
10/03/2002CA2440713A1 Nicotine-containing oral dosage form
10/03/2002CA2440582A1 Serum albumin binding moieties
10/03/2002CA2440387A1 Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
10/03/2002CA2437287A1 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
10/03/2002CA2436340A1 Histidine-rich glycoprotein
10/03/2002CA2436198A1 Process for obtaining lignan, pharmaceutical compositions and uses thereof
10/03/2002CA2410469A1 Improved forms of pharmaceutically active agents and method for manufacture thereof
10/03/2002CA2405453A1 Pharmaceutical composition containing camptothecin derivative and ph-adjusting substance
10/02/2002EP1245649A2 Low foam N-alkyltartarimide and N-alkylmalimide wetting agents
10/02/2002EP1245636A1 Composition for hydrogel, hydrogel, and use thereof
10/02/2002EP1245276A2 Improved solid media
10/02/2002EP1245249A2 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug
10/02/2002EP1245240A1 Skin-compatible hydrogel adhesives and personal care products containing them
10/02/2002EP1245238A2 Exotoxin ligand
10/02/2002EP1245233A1 System for stabilizing lacrimal fluid layer
10/02/2002EP1245231A2 Pharmaceutical formulations containing darifenacin
10/02/2002EP1244805A1 Viral core protein-cationic lipid-nucleic acid-delivery complexes
10/02/2002EP1244796A2 Transduction of recombinases for inducible gene targeting
10/02/2002EP1244657A2 Sulfonamides and derivatives thereof that modulate the activity of endothelin
10/02/2002EP1244630A1 Amphiphilic polyamines, the use and method for synthesis thereof
10/02/2002EP1244624A1 Anthracene derivatives as anti-cancer agents
10/02/2002EP1244472A2 Particulate vitamin composition
10/02/2002EP1244471A1 Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
10/02/2002EP1244468A2 Selective activation of a th1 or th2 lymphocyte regulated immune response
10/02/2002EP1244449A1 Use of ketotifen as ophthalmic agent
10/02/2002EP1244434A2 Use of chemotherapeutic agents
10/02/2002EP1244432A2 Methods for pulmonary delivery of interleukin-2
10/02/2002EP1244427A2 Pharmaceutical compositions for oral administration
10/02/2002EP1244418A2 Oil-in-water type cosmetic or dermatological preparations
10/02/2002EP1244401A1 Drug delivery of phase changing formulation
10/02/2002EP1244388A2 Intervertebral disc treatment devices and methods
10/02/2002EP1139762B1 Hydrogen peroxide disinfectant with increased activity
10/02/2002EP1123103B1 A process for producing an iron-dextran compound
10/02/2002EP1100803B1 Pyrrolo [2,1-b] [1,3]benzothiazepines with atypical antipsychotic activity
10/02/2002EP1079814B1 Electrostatic layering process and coated units obtained thereby
10/02/2002EP1071481B1 Preparation for regenerating collagen
10/02/2002EP0989851B1 Self-emulsifying formulation for acidic lipophilic compounds
1 ... 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 ... 1712